
Starting with Moderna announcing a cancer-curing vaccine last week that caused their stock to triple (and Moderna isn’t just some tiny biotech; this was tens of billions of dollars of value creation), and now RevMed announcing their drug Rasonque performing well, it seems like humans are winning some battles in our war against cancer.
These are both really important, not just as an investor but as a person operating in the world; cancer is a devastating issue that has plagued humanity for nearly all of history (I advise you checkout Emperor of All Maladies for those who haven’t read it) and we might just be pulling ahead. With these new releases, it is possible that a generation or two from today, we may have a cancer-free future.
What happened with Moderna?
Moderna and Merck announced that a drug they have been codeveloping, under the noncopyright name of mRNA-4157 can treat melanoma when paired with Merck’s Skytruda. Moderna stock, which was at the time 90% off of all time highs, jumped nearly 3x in one day. Billions of dollars of market cap in one day. They announced that their Phase 3 trial demonstrated statistical significance; the drug worked.
Essentially, here’s how it works. Someone with high risk melanoma sends a sample of their blood to the lab. The lab uses a computer scan to find the cancer’s “fingerprint” and picks up to 34 targets. These targets are then encoded, kind of like an address and directions, into an mRNA strand. This mRNA strand is wrapped in a lipid nanoparticle (LNP) for protection and delivery. The package alerts the immune system what it should be attacking. The immune system then delivers T-Cells and begins to kill the cancer.
This drug, when targeting melanoma, has an expected TAM of $3bn. When expanded to lung, kidney, and pancreatic cancer, this number comes to $50bn. The cost could reach up to $500,000 per patient.
What’s this other cancer drug you speak of?
Even more recently, RevMed announced FDA Approval for Rasonque. Rasonque targets pancreatic cancer. It does so by targeting the RAS Mutation, a common cause of many different types of cancer.
Simply put, RAS turns on and off cell growth in a normative body. Mutated RAS doesn’t ever turn it off, which makes cancer more likely. The problem is that RAS is historically hard to “latch onto.” It was called, “undruggable” because of it’s structure, by a scientist. But RevMed uses a compound glue, otherwise known as a helper, to latch onto RAS and stop the growth signal.
This doesn’t just stop new cancer from being generated. It also leads to existing cancer cells dying. That’s for two main reasons: oncogene addiction is a concept that cancer cells are highly dependent on one genetic component, namely the one that is the source of uncontrolled growth. Normal cells expect various different sources for their signaling on growth, metabolism, and more. Cancer cells look to one thing; for many, that thing is RAS. If you shut off RAS, growth and metabolism and more shuts down, but other healthy cells are able to operate normally. Also, apoptosis which is the process wherein a cell essentially kills itself, occurs among the cancer cells once you have neutralized the RAS. These cancer cells are essentially flooded with pro-survival signals, with the RAS continuing to tell them they must grow, and stay alive. For this reason, they never build the proper translator for pro-survival and pro-death signals. Once the RAS disappears, they have no more flood of pro-survival signals to drown out the pro-death signals.
Please note that I am not a doctor, and am not acutely aware of exactly what I’m talking about. Did my best here. Please fact check me or call me out if I was misleading.
Further reading for those who are interested here:
Please consider signing up for a paid subscription so you can learn about investments like Moderna, before the entire world finds out! Our paid subs get access to all of our actionable long-short theses, and also, they make this research possible. We need your support!